Increased use of illicit drugs in a Dutch cluster headache population.
Cluster headache
GHB
cannabis
heroin
psilocybin mushroom
Journal
Cephalalgia : an international journal of headache
ISSN: 1468-2982
Titre abrégé: Cephalalgia
Pays: England
ID NLM: 8200710
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
7
10
2018
medline:
21
10
2020
entrez:
7
10
2018
Statut:
ppublish
Résumé
Many patients with cluster headache report use of illicit drugs. We systematically assessed the use of illicit drugs and their effects in a well-defined Dutch cluster headache population. In this cross-sectional explorative study, 756 people with cluster headache received a questionnaire on lifetime use and perceived effects of illicit drugs. Results were compared with age and sex-matched official data from the Dutch general population. Compared to the data from the general population, there were more illicit drug users in the cluster headache group (31.7% vs. 23.8%; p < 0.01). Reduction in attack frequency was reported by 56% (n = 22) of psilocybin mushroom, 60% (n = 3) of lysergic acid diethylamide and 50% (n = 2) of heroin users, and a decreased attack duration was reported by 46% (n = 18) of PSI, 50% (n = 2) of heroin and 36% (n = 8) of amphetamine users. In the Netherlands, people with cluster headache use illicit drugs more often than the general population. The question remains whether this is due to an actual alleviatory effect, placebo response, conviction, or common pathophysiological background between cluster headache and addictive behaviours such as drug use.
Identifiants
pubmed: 30290701
doi: 10.1177/0333102418804160
pmc: PMC6484703
doi:
Substances chimiques
Illicit Drugs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
626-634Références
Cephalalgia. 2000 Mar;20(2):85-91
pubmed: 10961763
Soz Praventivmed. 2002;47(1):14-23
pubmed: 12050925
Brain. 2003 Jun;126(Pt 6):1252-70
pubmed: 12764049
Addiction. 2005 Jul;100(7):963-70
pubmed: 15955012
Lancet. 2005 Sep 3-9;366(9488):843-55
pubmed: 16139660
Neurology. 2006 Jun 27;66(12):1920-2
pubmed: 16801660
J Laryngol Otol. 2006 Oct;120(10):808-11
pubmed: 16848922
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1354-8
pubmed: 17442761
Cephalalgia. 2008 Jun;28(6):614-8
pubmed: 18422717
Complement Ther Med. 2008 Aug;16(4):220-7
pubmed: 18638713
Dis Mon. 2009 Jan;55(1):6-38
pubmed: 19081448
Headache. 2009 Jun;49(6):914-6
pubmed: 19220500
J Behav Med. 2010 Dec;33(6):474-85
pubmed: 20625809
Neurology. 2011 Jul 5;77(1):67-70
pubmed: 21613599
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
Headache. 2012 Apr;52(4):600-11
pubmed: 22077836
J Neurol Sci. 2012 Jun 15;317(1-2):17-28
pubmed: 22482825
BMJ. 2012 Apr 11;344:e2407
pubmed: 22496300
Cephalalgia. 2012 Oct;32(14):1031-40
pubmed: 22967729
Cephalalgia. 2012 Oct;32(14):1021-2
pubmed: 23043132
Cephalalgia. 2013 Feb;33(3):208-13
pubmed: 23197349
Headache. 2013 Oct;53(9):1490-1
pubmed: 23463909
Cephalalgia. 2013 Aug;33(11):924-31
pubmed: 23624341
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Curr Pain Headache Rep. 2014 May;18(5):413
pubmed: 24715619
Cephalalgia. 2016 Feb;36(2):194-8
pubmed: 25903763
Cephalalgia. 2016 May;36(6):547-51
pubmed: 26395893
Harm Reduct J. 2017 Sep 5;14(1):60
pubmed: 28870224
Lancet. 1998 Jul 25;352(9124):275-8
pubmed: 9690407